Overview

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.

Phase:

Phase 2

Details

Lead Sponsor:

Duke University

Collaborator:

Janssen Pharmaceuticals

Treatments:

Abiraterone Acetate
Androgens
Ascorbic Acid
Estrogens, Conjugated (USP)
Methyltestosterone
Prednisone